COMMUNIQUÉS West-GlobeNewswire

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development
10/07/2025
VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies [...]
Epitopea renforce ses capacités de recherche et de développement clinique pour accélérer le passage à la clinique
10/07/2025
CAMBRIDGE, Royaume-Uni et MONTRÉAL, 10 juill. 2025 (GLOBE NEWSWIRE) -- Epitopea, société transatlantique d'immunothérapie anticancéreuse développant des immunothérapies à base d'ARN accessibles et prêtes à l'emploi, a [...]
Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic
10/07/2025
CAMBRIDGE, United Kingdom and MONTREAL, July 10, 2025 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, today announced the [...]
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
10/07/2025
REYKJAVIK, Iceland, July 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the [...]
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
10/07/2025
REYKJAVIK, ICELAND (July 10, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of [...]
Osivax Publishes Phase 2a Results Supporting Co-Administration of OVX836 with Seasonal Flu Vaccine in Vaccines Journal
10/07/2025
Co-administration of OVX836 with seasonal inactivated influenza vaccine (Fluarix ® Tetra) was well-tolerated and demonstrated a favorable safety profile Robust complementary immune responses were induced, with no major [...]
Tecan announces CEO transition as part of succession planning
10/07/2025
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Männedorf, Switzerland, July 10, 2025 – The Tecan Group (SIX Swiss Exchange: TECN) today announced a planned CEO transition, [...]
DXS International plc (AQSE:DXSP): ExpertCare featured in Innovate UK Research Project
10/07/2025
DXS INTERNATIONAL PLC (AQSE: DXSP) ExpertCare featured in Innovate UK Research Project DXS International plc ("DXS" or "the Company"), a leading provider of digital clinical decision support solutions, is thrilled to [...]
Gozellix Receives Permanent HCPCS Code
10/07/2025
MELBOURNE, Australia and INDIANAPOLIS, July 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that its next-generation PSMA 1 PET 2 imaging agent, Gozellix® (kit [...]
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds
09/07/2025
SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with [...]
HNL Lab Medicine Named Empowering Women Award Recipient for 2025
09/07/2025
ALLENTOWN, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- HNL Lab Medicine has been named a recipient of the 2025 Empowering Women Award by Lehigh Valley Business and Central Penn Business Journal, in recognition of its strong [...]
Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
09/07/2025
Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and Waldenström [...]
Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine
09/07/2025
The previously disclosed and now published RESILIENT data show that once-nightly TNX-102 SL achieved statistically significant improvement in the primary endpoint of reducing fibromyalgia pain versus placebo, and was [...]
Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
09/07/2025
Data from Orbit and Cosmic studies expected around the end of the year NOVATO, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO), today [...]
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/07/2025
SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies [...]
Inventiva annonce la nomination de Jason Campagna en tant que Président de la R&D et Directeur Médical et de Martine Zimmermann en tant que Vice-Présidente Exécutive en charge des affaires réglementaires et de l’assurance qualité
09/07/2025
Jason Campagna, MD, PhD, rejoint Inventiva en tant que Président de la R&D et Directeur Médical, succédant à Pierre Broqua, PhD, et Michael Cooreman, MD Martine Zimmermann, PharmD, rejoint l'entreprise en tant que [...]
Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance
09/07/2025
Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MD Martine Zimmermann, PharmD, joins as Executive Vice President of [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
09/07/2025
ZUG, Switzerland, July 09, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to directors of the Company. Attachment Notification of managers' [...]
Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025
09/07/2025
RADNOR, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2025 [...]

Pages